//fpnotebook.com/
Menomune
Aka: Menomune, MPSV4, Quadrivalent Meningococcal Polysaccharide Vaccine
- See Also
- Meningococcal Vaccine (Menactra, Menveo, MCV4)
- Serotype B Meningococcal Vaccine ( Trumenba, Bexero)
- Neisseria Meningitidis
- Bacterial Meningitis
- Indications
- See Menactra (MCV4) which is preferred due to higher immunogenicity
- Mechanism
- Quadrivalent Meningococcal Polysaccharide Vaccine
- Covers strains A, C, W-135, and Y (does not contain B serotype)
- Covers same strains as Menactra
- See Menactra for further explanation
- Cost: $100 (similar to Menactra)
- Storage: 35 to 46 F (2 to 8 C), Same as Menactra
- Dose: Menomune
- Adult: 0.5 ml SC every 3 years
- Intramuscular may be preferred over subcutaneous route
- Intramuscular Injection reduces adverse effects
- Local erythema (11% for IM, 32% for SC)
- Headache (3% for IM and 12% for SC)
- Intramuscular has same efficacy as subcutaneous route
- Efficacy
- Like Menactra, Menomune has a high seroconversion rate (98%-100%)
- However Menomune duration is much shorter
- Menomune duration lasts 3 years in school age children and less in infants
- Precautions: Safety
- No longer contains Thimerosal
- Approved for all ages
- Safe in Human Immunodeficiency Virus (HIV)
- See Immunization in HIV
- Adverse effects
- Serious adverse events are uncommon (<1.3%)
- Headache
- Fever (in up to 3% of children)
- Local reactions (more common with Menactra)
- References
- Bilukha (2005) MMWR Recomm Rep 54(RR-7):1-21 [PubMed]
- Peter (2001) Pediatr Infect Dis J 20:311-2 [PubMed]
- Ruben (2001) Clin Infect Dis 32:170-2 [PubMed]